Travere Positioned To Seek Accelerated Approval In Rare Kidney Disorder

 
• By Joseph Haas
  
Human kidney on scientific background. 3d illustration
Travere's sparsentan is one of several candidates to be the first approved IgAN therapy

More from Clinical Trials

More from R&D